GLP-1 drugs as nootropics: what the science actually says

What did @thebiohackedlabs actually say?

The creator claims that tesofensine, which they call an "oral peptide," massively elevates brain-derived neurotrophic factor (BDNF), produces a laser-focused "flow state," and with prolonged use becomes "metabolic" and "shreds you." They say they take 50 micrograms daily and describe it as "the most amazing oral peptide" available. They also note some users can't sleep on 50 mcg and suggest halving the dose.

A few immediate problems with this framing. Tesofensine is not a peptide. The creator kind of acknowledges this mid-sentence, then walks it back. It's a small-molecule triple monoamine reuptake inhibitor, structurally unrelated to peptides. Calling it one, even casually, is the kind of imprecision that sends people down the wrong research rabbit hole. The BDNF claim and the "research chemical" sourcing context also deserve serious scrutiny.

Does the science back this up?

Tesofensine does have real clinical data behind it, but almost none of it involves BDNF, and essentially none of it is about cognitive enhancement in healthy people. The bulk of the evidence is about weight loss in people with obesity.

The most-cited trial is Astrup et al. (2008, The Lancet), a randomized controlled trial in 203 patients with obesity. Participants taking 0.5 mg of tesofensine daily lost about 12.8 kg over 24 weeks, compared to 2.2 kg with placebo. That's a real and significant weight loss effect, driven by appetite suppression and increased energy expenditure via its action on serotonin, dopamine, and norepinephrine reuptake. A follow-up study, Sjödin et al. (2010, Diabetes, Obesity and Metabolism), confirmed metabolic effects including reduced fat mass.

The BDNF angle is murkier. There is preclinical work suggesting monoamine reuptake inhibition can upregulate BDNF expression, particularly through norepinephrine and serotonin pathways. Martinowich and Lu (2008, Neuropsychopharmacology) reviewed this mechanism. But the creator's claim that tesofensine raises BDNF "through the roof" in humans, producing flow states, is not supported by published clinical trials. No peer-reviewed human study has measured tesofensine's effect on BDNF or validated its use as a cognitive enhancer.

What did they get wrong (or right)?

They got the weight loss effect directionally correct. Tesofensine does produce meaningful fat loss, and the mechanism, triple monoamine reuptake inhibition, is biologically plausible for both appetite suppression and metabolic effects. Credit where it's due.

But several things are wrong or poorly framed. First, calling it a peptide is factually incorrect. Tesofensine is a piperidine-derived small molecule. Second, the BDNF claim is mechanistically speculative and not clinically validated in humans at the doses being discussed. Third, describing it as something you'd take for content creation and focus, and comparing it to dihexa (another experimental BDNF-related compound), treats two inadequately studied research chemicals as if they were settled ergogenics. Fourth, the framing around "research chemical companies" making half-dose capsules normalizes purchasing unapproved compounds from unregulated sources. Tesofensine never received FDA approval. It is not a legal supplement in the United States. Sourcing it from "research chemical companies" carries real risks around purity, dosing accuracy, and legal exposure that the creator does not mention.

• "It's not technically a peptide" - correct, but they kept calling it one anyway
• BDNF elevation in humans at these doses: no clinical evidence
• Fat loss effect: supported by RCT data
• Stimulant side effects including insomnia: consistent with its pharmacology

What should you actually know?

Tesofensine is a real compound with real pharmacological activity. The weight loss data from the Astrup et al. Lancet trial is legitimate and has been replicated. The stimulant-like side effects the creator describes, insomnia, overstimulation, dose sensitivity, are exactly what you'd predict from a triple reuptake inhibitor. That part checks out pharmacologically.

What doesn't check out is the cognitive enhancement narrative. The "flow state" and BDNF framing is speculative extrapolation, not evidence. And the context here matters: this compound has never been FDA-approved, is being purchased from unregulated research chemical vendors, and is being recommended to a general social media audience for productivity and content creation. That combination should give anyone pause.

If you're interested in BDNF-related approaches to cognition, there are better-studied, legal options. Exercise remains the most robustly validated BDNF upregulator in humans (Szuhany et al., 2015, Journal of Psychiatric Research). Anything beyond that, especially unapproved compounds from grey-market vendors, requires a conversation with a licensed clinician who can assess your individual risk profile.